Kezar Life Sciences, Inc.
KZR
$3.98
-$0.025-0.63%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 9.58M | -- | 16.03M | 16.24M | 16.30M |
| Gross Profit | -9.58M | -- | -16.03M | -16.24M | -16.30M |
| SG&A Expenses | 5.02M | 5.45M | 5.55M | 5.71M | 5.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.60M | 17.63M | 21.58M | 21.95M | 21.90M |
| Operating Income | -14.60M | -17.63M | -21.58M | -21.95M | -21.90M |
| Income Before Tax | -13.70M | -16.56M | -20.22M | -20.31M | -21.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.70M | -16.56M | -20.22M | -20.31M | -21.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.70M | -16.56M | -20.22M | -20.31M | -21.55M |
| EBIT | -14.60M | -17.63M | -21.58M | -21.95M | -21.90M |
| EBITDA | -14.36M | -17.38M | -21.32M | -21.69M | -21.64M |
| EPS Basic | -1.87 | -2.27 | -5.54 | -2.78 | -2.96 |
| Normalized Basic EPS | -1.17 | -1.42 | -3.46 | -1.74 | -1.72 |
| EPS Diluted | -1.87 | -2.27 | -5.54 | -2.78 | -2.96 |
| Normalized Diluted EPS | -1.17 | -1.42 | -3.46 | -1.74 | -1.72 |
| Average Basic Shares Outstanding | 7.31M | 7.31M | 7.30M | 7.30M | 7.28M |
| Average Diluted Shares Outstanding | 7.31M | 7.31M | 7.30M | 7.30M | 7.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |